1
|
Trimpin S, Inutan ED, Pagnotti VS, Karki S, Marshall DD, Hoang K, Wang B, Lietz CB, Richards AL, Yenchick FS, Lee C, Lu IC, Fenner M, Madarshahian S, Saylor S, Chubatyi ND, Zimmerman T, Moreno-Pedraza A, Wang T, Adeniji-Adele A, Meher AK, Madagedara H, Owczarzak Z, Musavi A, Hendrickson TL, Peacock PM, Tomsho JW, Larsen BS, Prokai L, Shulaev V, Pophristic M, McEwen CN. Direct sub-atmospheric pressure ionization mass spectrometry: Evaporation/sublimation-driven ionization is amazing, fundamentally, and practically. J Mass Spectrom 2024; 59:e5018. [PMID: 38736378 DOI: 10.1002/jms.5018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 12/08/2023] [Accepted: 03/04/2024] [Indexed: 05/14/2024]
Abstract
This paper covers direct sub-atmospheric pressure ionization mass spectrometry (MS). The discovery, applications, and mechanistic aspects of novel ionization processes for use in MS that are not based on the high-energy input from voltage, laser, and/or high temperature but on sublimation/evaporation within a region linking a higher to lower pressure and modulated by heat and collisions, are discussed, including how this new reality has guided a series of discoveries, instrument developments, and commercialization. A research focus, inter alia, is on how best to understand, improve, and use these novel ionization processes, which convert volatile and nonvolatile compounds from solids (sublimation) or liquids (evaporation) into gas-phase ions for analysis by MS providing reproducible, accurate, sensitive, and prompt results. Our perception on how these unprecedented versus traditional ionization processes/methods relate to each other, how they can be made to coexist on the same mass spectrometer, and an outlook on new and expanded applications (e.g., clinical, portable, fast, safe, and autonomous) is presented, and is based on ST's Opening lecture presentation at the Nordic Mass spectrometry Conference, Geilo, Norway, January 2023. Focus will be on matrix-assisted ionization (MAI) and solvent-assisted ionization (SAI) MS covering the period from 2010 to 2023; a potential paradigm shift in the making.
Collapse
Affiliation(s)
- Sarah Trimpin
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
- MSTM, LLC, Newark, Delaware, USA
| | - Ellen D Inutan
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
- MSTM, LLC, Newark, Delaware, USA
- Mindanao State University-Iligan Institute of Technology, Iligan City, Philippines
| | - Vincent S Pagnotti
- Department of Chemistry & Biochemistry, Saint Joseph's University, Philadelphia, Pennsylvania, USA
| | - Santosh Karki
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
- MSTM, LLC, Newark, Delaware, USA
| | - Darrell D Marshall
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
- MSTM, LLC, Newark, Delaware, USA
| | - Khoa Hoang
- MSTM, LLC, Newark, Delaware, USA
- Department of Chemistry & Biochemistry, Saint Joseph's University, Philadelphia, Pennsylvania, USA
| | - Beixi Wang
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
| | | | - Alicia L Richards
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
| | - Frank S Yenchick
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
| | - Chuping Lee
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
| | - I-Chung Lu
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
- Department of Chemistry, National Chung Hsing University, Taichung, Taiwan
| | - Madeleine Fenner
- Department of Chemistry & Biochemistry, Saint Joseph's University, Philadelphia, Pennsylvania, USA
| | - Sara Madarshahian
- Department of Chemistry & Biochemistry, Saint Joseph's University, Philadelphia, Pennsylvania, USA
| | - Sarah Saylor
- Department of Chemistry & Biochemistry, Saint Joseph's University, Philadelphia, Pennsylvania, USA
| | - Nicolas D Chubatyi
- Department of Chemistry & Biochemistry, Saint Joseph's University, Philadelphia, Pennsylvania, USA
| | - Teresa Zimmerman
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
| | | | - Tongwen Wang
- Department of Chemistry & Biochemistry, Saint Joseph's University, Philadelphia, Pennsylvania, USA
| | - Adetoun Adeniji-Adele
- Department of Chemistry & Biochemistry, Saint Joseph's University, Philadelphia, Pennsylvania, USA
| | - Anil K Meher
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
- MSTM, LLC, Newark, Delaware, USA
| | - Hasini Madagedara
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
| | - Zachary Owczarzak
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
| | - Ahmed Musavi
- Department of Chemistry, Wayne State University, Detroit, Michigan, USA
| | | | | | - John W Tomsho
- Department of Chemistry & Biochemistry, Saint Joseph's University, Philadelphia, Pennsylvania, USA
| | | | - Laszlo Prokai
- Department of Pharmacology and Neuroscience, The University of North Texas Health Science Center at Forth Worth, Fort Worth, Texas, USA
| | - Vladimir Shulaev
- Department of Biological Sciences, The University of North Texas, Denton, Texas, USA
| | - Milan Pophristic
- MSTM, LLC, Newark, Delaware, USA
- Department of Chemistry & Biochemistry, Saint Joseph's University, Philadelphia, Pennsylvania, USA
| | - Charles N McEwen
- MSTM, LLC, Newark, Delaware, USA
- Department of Chemistry & Biochemistry, Saint Joseph's University, Philadelphia, Pennsylvania, USA
| |
Collapse
|
2
|
Shah B, Yang K, Klink A, Liu T, Zimmerman T, Gajra A, Tang B. P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA. Hemasphere 2022. [PMCID: PMC9431325 DOI: 10.1097/01.hs9.0000847496.16686.fc] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Ledingham L, Tatsuoka C, Minich N, Ross KR, Kerns LA, Wagner CL, Fuloria M, Groh-Wargo S, Zimmerman T, Hibbs AM. Burden of prematurity-associated recurrent wheezing: caregiver missed work in the D-Wheeze trial. J Perinatol 2021; 41:69-76. [PMID: 32694857 PMCID: PMC7855497 DOI: 10.1038/s41372-020-0729-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2020] [Revised: 05/31/2020] [Accepted: 07/07/2020] [Indexed: 11/28/2022]
Abstract
OBJECTIVE This study describes the burden of prematurity-associated wheezing in black infants with respect to caregiver missed work. STUDY DESIGN We analyzed data from the D-Wheeze trial (ClinicalTrials.gov identifier NCT01601847). Black infants between 28-0/7 to 36-6/7 weeks' gestational age at birth receiving <28 days of supplemental oxygen were enrolled. The primary outcome was missed work to care for the infant in the first year. RESULTS 147/277 (53.1%) infants had caregivers who reported time off. In an adjusted model, vitamin D supplementation (OR 0.52 [95% CI 0.30-0.89]; P = 0.018), recurrent wheeze (OR 2.26 [95% CI, 1.15-4.44]; P = 0.018), and other children in the household <5 years old (OR 0.45 [95% CI 0.26-0.78]; P = 0.004) were significantly associated with caregiver missed work. CONCLUSIONS Black premature infants had a significant burden of caregiver missed work, emphasizing the impact of prematurity-associated wheezing.
Collapse
Affiliation(s)
- Lauren Ledingham
- Case Western Reserve University, Cleveland, OH, USA. .,UH Rainbow Babies and Children's Hospital, Cleveland, OH, USA.
| | - Curtis Tatsuoka
- Case Western Reserve University, Cleveland, OH,University Hospitals Cleveland Medical Center, Cleveland, OH
| | - Nori Minich
- Case Western Reserve University, Cleveland, OH,UH Rainbow Babies and Children’s Hospital, Cleveland, OH
| | - Kristie R. Ross
- Case Western Reserve University, Cleveland, OH,UH Rainbow Babies and Children’s Hospital, Cleveland, OH
| | - Leigh Ann Kerns
- Case Western Reserve University, Cleveland, OH,Cleveland Clinic Foundation, Cleveland, OH
| | - Carol L. Wagner
- Shawn Jenkins Children’s Hospital, Medical University of South Carolina, Charleston, South Carolina
| | - Mamta Fuloria
- The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York
| | - Sharon Groh-Wargo
- Case Western Reserve University, Cleveland, OH,MetroHealth Medical Center, Cleveland, Ohio
| | - Teresa Zimmerman
- Case Western Reserve University, Cleveland, OH,UH Rainbow Babies and Children’s Hospital, Cleveland, OH
| | - Anna Maria Hibbs
- Case Western Reserve University, Cleveland, OH,UH Rainbow Babies and Children’s Hospital, Cleveland, OH
| |
Collapse
|
4
|
Hibbs AM, Ross K, Kerns LA, Wagner C, Fuloria M, Groh-Wargo S, Zimmerman T, Minich N, Tatsuoka C. Effect of Vitamin D Supplementation on Recurrent Wheezing in Black Infants Who Were Born Preterm: The D-Wheeze Randomized Clinical Trial. JAMA 2018; 319:2086-2094. [PMID: 29800180 PMCID: PMC6583240 DOI: 10.1001/jama.2018.5729] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
IMPORTANCE Black infants born preterm face high rates of recurrent wheezing throughout infancy. Vitamin D supplementation has the potential to positively or negatively affect wheezing through modulation of the pulmonary and immune systems. OBJECTIVE To assess the effectiveness of 2 vitamin D dosing strategies in preventing recurrent wheezing. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial enrolled 300 black infants born at 28 to 36 weeks' gestation between January 2013 and January 2016 at 4 sites in the United States, and followed them up through March 2017. Randomization was stratified by site and maternal milk exposure. INTERVENTIONS Patients were enrolled prior to discharge from the neonatal intensive care unit or newborn nursery and received open-label multivitamin until they were consuming 200 IU/d of cholecalciferol from formula or fortifier added to human milk, after which they received either 400 IU/d of cholecalciferol until 6 months of age adjusted for prematurity (sustained supplementation) or placebo (diet-limited supplementation). One-hundred fifty three infants were randomized to the sustained group, and 147 were randomized to the diet-limited group. MAIN OUTCOMES AND MEASURES Recurrent wheezing by 12 months' adjusted age was the primary outcome. RESULTS Among 300 patients who were randomized (mean gestational age, 33 weeks; median birth weight, 1.9 kg), 277 (92.3%) completed the trial. Recurrent wheezing was experienced by 31.1% of infants in the sustained supplementation group and 41.8% of infants in the diet-limited supplementation group (difference, -10.7% [95% CI, -27.4% to -2.9%]; relative risk, 0.66 [95% CI, 0.47 to 0.94]). Upper and lower respiratory tract infections were among the most commonly reported adverse events. Upper respiratory infections were experienced by 84 of 153 infants (54.9%) in the sustained group and 83 of 147 infants (56.5%) in the diet-limited group (difference, -1.6% [95% CI, -17.1% to 7.0%]). Lower respiratory infections were experienced by 33 of 153 infants (21.6%) in the sustained group and 37 of 147 infants (25.2%) in the diet-limited group (difference, -3.6% [95% CI, -16.4% to 4.4%]). CONCLUSIONS AND RELEVANCE Among black infants born preterm, sustained supplementation with vitamin D, compared with diet-limited supplementation, resulted in a reduced risk of recurrent wheezing by 12 months' adjusted age. Future research is needed to better understand the mechanisms and longer-term effects of vitamin D supplementation on wheezing in children born preterm. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01601847.
Collapse
Affiliation(s)
- Anna Maria Hibbs
- Case Western Reserve University, Cleveland, Ohio
- University Hospitals Cleveland Medical Center, Cleveland, Ohio
| | - Kristie Ross
- Case Western Reserve University, Cleveland, Ohio
- University Hospitals Cleveland Medical Center, Cleveland, Ohio
| | - Leigh Ann Kerns
- Case Western Reserve University, Cleveland, Ohio
- University Hospitals Cleveland Medical Center, Cleveland, Ohio
| | - Carol Wagner
- Shawn Jenkins Children’s Hospital, Medical University of South Carolina, Charleston
| | - Mamta Fuloria
- The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York
| | - Sharon Groh-Wargo
- Case Western Reserve University, Cleveland, Ohio
- MetroHealth Medical Center, Cleveland, Ohio
| | - Teresa Zimmerman
- Case Western Reserve University, Cleveland, Ohio
- University Hospitals Cleveland Medical Center, Cleveland, Ohio
| | - Nori Minich
- Case Western Reserve University, Cleveland, Ohio
- University Hospitals Cleveland Medical Center, Cleveland, Ohio
| | - Curtis Tatsuoka
- Case Western Reserve University, Cleveland, Ohio
- University Hospitals Cleveland Medical Center, Cleveland, Ohio
| |
Collapse
|
5
|
Harb W, Garner F, McDermott J, Zimmerman T, Williams G, Hattersley G, Purandare D. Abstract OT2-01-10: A phase 1 study of RAD1901, a novel, orally available, selective estrogen receptor degrader, for the treatment of ER positive advanced breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot2-01-10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The current NCCN treatment guidelines for ER+ breast cancer involves the use of approved agents such as fulvestrant, tamoxifen and aromatase inhibitors that either inhibit estrogen production or block estrogen receptor binding. While the initial treatment regimens with these selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) is often successful, many women eventually relapse with more aggressive forms of endocrine-resistant disease. To begin to overcome some of the challenges associated with current therapies including exposure limitations and intramuscular administration, we have developed RAD1901, a novel, non-steroidal, orally available SERD. Preclinical studies with RAD1901 have demonstrated potent dose dependent ER degradation consistent with a SERD mechanism of action, as well as potent inhibition of proliferation in vitro in breast cancer cell lines. RAD1901 also demonstrated significant anti-tumor efficacy in vivo, and notably single agent regressions in both MCF7 and a primary patient derived xenograft models harboring an ESR1 mutations.
A phase 1 monotherapy study conducted in healthy postmenopausal female volunteers evaluated forty four subjects treated once daily with RAD1901 with doses ranging from 200 mg/day up to 1000 mg/day for 7 days. All dose levels were generally well tolerated and pharmacokinetic analysis demonstrated plasma exposures consistent with preclinical efficacy in ER+ breast cancer models. Furthermore, 18F-estradiol positron emission tomography (FES-PET) was also performed at baseline and after 7 days of RAD1901 treatment, to evaluate estrogen receptor engagement. Standardized uptake values (SUV) pre- and post-treatment with RAD1901 demonstrated complete attenuation of FES-PET signal in ER+ tissues such as the uterus from the 200 mg/day dose level. Taken together, these results provide strong preclinical and clinical rationale for the development of RAD1901 as a potent and selective oral SERD for the treatment of hormone driven and hormone resistant ER + metastatic breast cancers.
RAD1901-005 is a Phase 1 study currently enrolling ER+ advanced metastatic breast cancer patients. The study consists of two parts: a monotherapy dose escalation followed by a safety expansion at the maximum tolerated dose (MTD). The dose escalation will follow a standard 3+3 design with once daily dosing to establish, safety, tolerability, and PK. Once the MTD for RAD1901 has been established, the safety expansion will further evaluate the safety, tolerability, biomarkers and preliminary efficacy at the recommended phase 2 dose (RP2D) following a continuous once daily schedule. Key inclusion criteria include post-menopausal women aged 18 years or older, with advanced ER positive, HER2 negative breast cancer, who have received ≤ 2 prior chemotherapy regimens in the metastatic setting and > 6 months of prior endocrine therapy. Patient enrollment started in early 2015, and is currently ongoing.
ClinicalTrials.gov identifier: NCT02338349.
Citation Format: Harb W, Garner F, McDermott J, Zimmerman T, Williams G, Hattersley G, Purandare D. A phase 1 study of RAD1901, a novel, orally available, selective estrogen receptor degrader, for the treatment of ER positive advanced breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT2-01-10.
Collapse
Affiliation(s)
- W Harb
- Horizon Oncology Center; Radius Health Inc
| | - F Garner
- Horizon Oncology Center; Radius Health Inc
| | | | | | - G Williams
- Horizon Oncology Center; Radius Health Inc
| | | | | |
Collapse
|
6
|
Sanchez-Lopez E, Zimmerman T, Gomez del Pulgar T, Moyer MP, Lacal Sanjuan JC, Cebrian A. Choline kinase inhibition induces exacerbated endoplasmic reticulum stress and triggers apoptosis via CHOP in cancer cells. Cell Death Dis 2013; 4:e933. [PMID: 24287694 PMCID: PMC3847329 DOI: 10.1038/cddis.2013.453] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2013] [Revised: 10/06/2013] [Accepted: 10/14/2013] [Indexed: 11/09/2022]
Abstract
Endoplasmic reticulum (ER) is a central organelle in eukaryotic cells that regulates protein synthesis and maturation. Perturbation of ER functions leads to ER stress, which has been previously associated with a broad variety of diseases. ER stress is generally regarded as compensatory, but prolonged ER stress has been involved in apoptosis induced by several cytotoxic agents. Choline kinase α (ChoKα), the first enzyme in the Kennedy pathway, is responsible for the generation of phosphorylcholine (PCho) that ultimately renders phosphatidylcholine. ChoKα overexpression and high PCho levels have been detected in several cancer types. Inhibition of ChoKα has demonstrated antiproliferative and antitumor properties; however, the mechanisms underlying these activities remain poorly understood. Here, we demonstrate that ChoKα inhibitors (ChoKIs), MN58b and RSM932A, induce cell death in cancer cells (T47D, MCF7, MDA-MB231, SW620 and H460), through the prolonged activation of ER stress response. Evidence of ChoKIs-induced ER stress includes enhanced production of glucose-regulated protein, 78 kDa (GRP78), protein disulfide isomerase, IRE1α, CHOP, CCAAT/enhancer-binding protein beta (C/EBPβ) and TRB3. Although partial reduction of ChoKα levels by small interfering RNA was not sufficient to increase the production of ER stress proteins, silencing of ChoKα levels also show a decrease in CHOP overproduction induced by ChoKIs, which suggests that ER stress induction is due to a change in ChoKα protein folding after binding to ChoKIs. Silencing of CHOP expression leads to a reduction in C/EBPβ, ATF3 and GRP78 protein levels and abrogates apoptosis in tumor cells after treatment with ChoKIs, suggesting that CHOP maintains ER stress responses and triggers the pro-apoptotic signal. Consistent with the differential effect of ChoKIs in cancer and primary cells previously described, ChoKIs only promoted a transient and moderated ER stress response in the non-tumorogenic cells MCF10A. In conclusion, pharmacological inhibition of ChoKα induces cancer cell death through a mechanism that involves the activation of exaggerated and persistent ER stress supported by CHOP overproduction.
Collapse
Affiliation(s)
- E Sanchez-Lopez
- Department of Pharmacology, School of Medicine, UCSD, San Diego, CA, USA
| | | | | | | | | | | |
Collapse
|
7
|
Hofmeister CC, Richardson P, Zimmerman T, Spear MA, Palladino MA, Longenecker AM, Cropp GF, Lloyd GK, Hannah AL, Anderson K. Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8505] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8505 Background: NPI-0052 produces rapid, broad and prolonged inhibition of all 3 catalytic activities of the 20S proteasome. NPI-0052 has a non-peptide based structure that appears to result in a unique proteasome inhibition (PI), signal transduction and safety profile. Preclinical data suggest NPI-0052 may demonstrate an improved therapeutic ratio, with significant activity in hematologic and solid tumor malignancies including MM resistant to bortezomib (BZ) and other agents. Methods: This phase I dose escalation study of NPI-0052 was conducted in patients (pts) with r/r MM, including after BZ and/or lenalidomide. Pts were treated with NPI-0052 IV weekly for 3 weeks in 4-week cycles. The dose of NPI-0052 was escalated utilizing a combination of accelerated titration and 3+3 designs. PI and PK were assayed after the 1st and 3rd doses. Results: 17 patients have been treated at doses ranging from 0.025 mg/m2 to 0.6 mg/m2 without reaching a MTD. One patient experienced reversible creatinine elevation associated with progression of light chain nephropathy at 0.075 mg/m2. Drug- related adverse events have consisted principally of mild-to-moderate fatigue, nausea and diarrhea. In this study at dose levels 0.75 and 0.15 mg/m2, the half-life = 0.5 - 5.0 min; clearance = 4.8 ± 5.2 L/min and Vz = 22.6 ± 44.2 L. PI in whole blood demonstrates dose-dependent chymotrypsin-like inhibition up to 26% at 0.075 mg/m2. Of note, 2 patients remained on study for over 6 months and one year with stable disease and no significant toxicity. Importantly, NPI-0052 does not appear to induce peripheral neuropathy or myelosuppression. Conclusions: NPI-0052 was well tolerated in this study with escalation continuing to a recommended phase II dose (RP2D) for r/r MM. The RP2D (0.7 - 0.8 mg/m2), PI and safety profiles of NPI-0052 have been defined in other diagnoses, and appear unique from BZ in spite of up to 100% proteasome inhibition. In this study, NPI-0052 has effects on PD, PK and may potentially confer clinical benefit at doses which are well below the MTD determined in the other trials. Additional trials in MM are being initiated, including with lenalidomide. [Table: see text]
Collapse
Affiliation(s)
- C. C. Hofmeister
- The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; Nereus Pharmaceuticals, San Diego, CA; Multiple Myeloma Research Consortium, Norwalk, CT
| | - P. Richardson
- The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; Nereus Pharmaceuticals, San Diego, CA; Multiple Myeloma Research Consortium, Norwalk, CT
| | - T. Zimmerman
- The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; Nereus Pharmaceuticals, San Diego, CA; Multiple Myeloma Research Consortium, Norwalk, CT
| | - M. A. Spear
- The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; Nereus Pharmaceuticals, San Diego, CA; Multiple Myeloma Research Consortium, Norwalk, CT
| | - M. A. Palladino
- The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; Nereus Pharmaceuticals, San Diego, CA; Multiple Myeloma Research Consortium, Norwalk, CT
| | - A. M. Longenecker
- The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; Nereus Pharmaceuticals, San Diego, CA; Multiple Myeloma Research Consortium, Norwalk, CT
| | - G. F. Cropp
- The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; Nereus Pharmaceuticals, San Diego, CA; Multiple Myeloma Research Consortium, Norwalk, CT
| | - G. K. Lloyd
- The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; Nereus Pharmaceuticals, San Diego, CA; Multiple Myeloma Research Consortium, Norwalk, CT
| | - A. L. Hannah
- The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; Nereus Pharmaceuticals, San Diego, CA; Multiple Myeloma Research Consortium, Norwalk, CT
| | - K. Anderson
- The Ohio State University, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; University of Chicago, Chicago, IL; Nereus Pharmaceuticals, San Diego, CA; Multiple Myeloma Research Consortium, Norwalk, CT
| |
Collapse
|
8
|
Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM, Rich E, Smith SM, Zimmerman T, Zhang Y, Huo D, Larson R, van Besien K. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007; 40:1027-32. [PMID: 17846595 DOI: 10.1038/sj.bmt.1705852] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We describe treatment, outcomes and prognostic factors for patients who relapse following transplantation with a reduced intensity conditioning regimen. Seventy consecutive patients with high-risk myeloid malignancies underwent transplant and 25 (36%) relapsed, a median of 120 days later. The median percentage of bone marrow blasts at relapse was 24, the median donor chimerism was 73% and new karyotypic abnormalities occurred in 8 out of 20 (40%) evaluable patients. Twenty-one patients (84%) received aggressive treatment for relapse, including chemotherapy (60%), second hematopoietic cell transplantation (HCT; 52%) and/or donor lymphocyte infusion (DLI; 12%). Thirteen achieved a complete response (CR) and four remain in CR. Median overall survival (OS) after relapse was 6 months (95% confidence interval=2.7-9.9 months), and actuarial 1 year OS was 24%. Most deaths were due to disease progression (17/20, 85%). We did not observe an advantage for cellular therapy (DLI or second transplant) compared to chemotherapy. Salvage therapy for relapse after reduced intensity HCT is feasible, associated with low treatment-related mortality, and may result in prolonged survival in select patients. Studies exploring the optimal treatment for relapse following reduced intensity HCT are warranted.
Collapse
Affiliation(s)
- D A Pollyea
- Department of Internal Medicine, University of Chicago Hospitals, Chicago, IL 60637, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Cripe L, McGuire W, Wertheim M, Eisenberg P, Stadler W, Paquette R, Logan T, Zimmerman T, Matei D, Matulonis U. Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3591] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3591 Background: XL999 is a potent spectrum-selective inhibitor of tyrosine kinases including VEGFR2/KDR, FGFR1/3, PDGFR-β, FLT3, RET, KIT, & SRC. A Ph 1 study in pts w/advanced malignancies has shown anti-tumor activity (3 PRs &10 SD lasting 3–26+ months) DLTs were cardiac failure & transaminase elevation. Methods: XL999 is being investigated in 6 Ph 2 trials. Pts w/histologically confirmed NSCLC, RCC, CRC, recurrent ovarian CA, AML, & MM were enrolled. The primary objectives of these independent studies are to determine response rate and further evaluate safety and tolerability of XL999. The secondary objectives are to assess PFS, duration of response & OS. Pts receive a once wkly 4hr IV administration of XL999 (2.4 mg/kg). Tumor response is assessed every 8 wks. Results: A total of 79 pts were treated. A confirmed PR was reported in 1/ 9 pts w/NSCLC. An additional 2 pts have SD at 2 & 3 months w/1 showing tumor shrinkage (24%). Two of 11 pts w/RCC have SD at 2 & 4 months. Of 14 pts enrolled w/AML, 1 of 3 with an activating FLT3 mutation had a PR, and 8 of 10 w/circulating myeloblasts had >50% reduction in myeloblasts. AEs = Grade 2 in =10% of pts related to XL999 included N/V, constipation, diarrhea, dry mouth, oral hypoesthesia, fatigue, pyrexia, dizziness, dysguesia, & hypertension. Cardiovascular (CV) events considered SAEs were reported in 11 pts (14%), and all but 1 occurred with the 1st dose of XL999.These events were characterized by ST /T wave changes in ECG,LVEF decreases and /or troponin elevation. Most pts with CV SAEs recovered to baseline within 2–3 wks upon withdrawl of further XL999. Conclusions: XL999 administered IV at a dose of 2.4mg/kg wkly was associated w/CV AEs, the majority of which were associated w/the 1st dose and were generally reversible upon XL999 discontinuation. XL999 shows preliminary evidence of anti- tumor activity in pts w/NSCLC & AML. [Table: see text]
Collapse
Affiliation(s)
- L. Cripe
- Indiana University Cancer Center, Indianapolis, IN; Weinberg Cancer Institute at Franklin Square, Baltimore, MD; Hematology Oncology Associates of Treasure Coast, Port St. Lucie, FL; California Cancer Care, Greenbrae, CA; University of Chicago, Chicago, IL; University of California, Los Angeles, Los Angeles, CA; Center for Advanced Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA
| | - W. McGuire
- Indiana University Cancer Center, Indianapolis, IN; Weinberg Cancer Institute at Franklin Square, Baltimore, MD; Hematology Oncology Associates of Treasure Coast, Port St. Lucie, FL; California Cancer Care, Greenbrae, CA; University of Chicago, Chicago, IL; University of California, Los Angeles, Los Angeles, CA; Center for Advanced Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA
| | - M. Wertheim
- Indiana University Cancer Center, Indianapolis, IN; Weinberg Cancer Institute at Franklin Square, Baltimore, MD; Hematology Oncology Associates of Treasure Coast, Port St. Lucie, FL; California Cancer Care, Greenbrae, CA; University of Chicago, Chicago, IL; University of California, Los Angeles, Los Angeles, CA; Center for Advanced Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA
| | - P. Eisenberg
- Indiana University Cancer Center, Indianapolis, IN; Weinberg Cancer Institute at Franklin Square, Baltimore, MD; Hematology Oncology Associates of Treasure Coast, Port St. Lucie, FL; California Cancer Care, Greenbrae, CA; University of Chicago, Chicago, IL; University of California, Los Angeles, Los Angeles, CA; Center for Advanced Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA
| | - W. Stadler
- Indiana University Cancer Center, Indianapolis, IN; Weinberg Cancer Institute at Franklin Square, Baltimore, MD; Hematology Oncology Associates of Treasure Coast, Port St. Lucie, FL; California Cancer Care, Greenbrae, CA; University of Chicago, Chicago, IL; University of California, Los Angeles, Los Angeles, CA; Center for Advanced Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA
| | - R. Paquette
- Indiana University Cancer Center, Indianapolis, IN; Weinberg Cancer Institute at Franklin Square, Baltimore, MD; Hematology Oncology Associates of Treasure Coast, Port St. Lucie, FL; California Cancer Care, Greenbrae, CA; University of Chicago, Chicago, IL; University of California, Los Angeles, Los Angeles, CA; Center for Advanced Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA
| | - T. Logan
- Indiana University Cancer Center, Indianapolis, IN; Weinberg Cancer Institute at Franklin Square, Baltimore, MD; Hematology Oncology Associates of Treasure Coast, Port St. Lucie, FL; California Cancer Care, Greenbrae, CA; University of Chicago, Chicago, IL; University of California, Los Angeles, Los Angeles, CA; Center for Advanced Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA
| | - T. Zimmerman
- Indiana University Cancer Center, Indianapolis, IN; Weinberg Cancer Institute at Franklin Square, Baltimore, MD; Hematology Oncology Associates of Treasure Coast, Port St. Lucie, FL; California Cancer Care, Greenbrae, CA; University of Chicago, Chicago, IL; University of California, Los Angeles, Los Angeles, CA; Center for Advanced Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA
| | - D. Matei
- Indiana University Cancer Center, Indianapolis, IN; Weinberg Cancer Institute at Franklin Square, Baltimore, MD; Hematology Oncology Associates of Treasure Coast, Port St. Lucie, FL; California Cancer Care, Greenbrae, CA; University of Chicago, Chicago, IL; University of California, Los Angeles, Los Angeles, CA; Center for Advanced Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA
| | - U. Matulonis
- Indiana University Cancer Center, Indianapolis, IN; Weinberg Cancer Institute at Franklin Square, Baltimore, MD; Hematology Oncology Associates of Treasure Coast, Port St. Lucie, FL; California Cancer Care, Greenbrae, CA; University of Chicago, Chicago, IL; University of California, Los Angeles, Los Angeles, CA; Center for Advanced Medicine, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
10
|
Singer A, McClain S, Zimmerman T, Romanov A, Rooney J. The Effect of N-acetyl Cysteine on Burn Progression in Rats. Acad Emerg Med 2007. [DOI: 10.1197/j.aem.2007.03.747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
11
|
Singer A, McClain S, Romanov A, Rooney J, Zimmerman T. Validation of an Ischemic Comb Burn Model in Swine. Acad Emerg Med 2007. [DOI: 10.1197/j.aem.2007.03.746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
12
|
Singer A, McClain S, Romanov A, Rooney J, Zimmerman T. Curcumin Reduces Burn Progression in Rats. Acad Emerg Med 2007. [DOI: 10.1197/j.aem.2007.03.1116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
13
|
Singer A, Huang J, McClain S, Romanov A, Rooney J, Zimmerman T, Huang S. A Novel TGF-Beta Antagonist Speeds Reepithelialization and Reduces Scarring of Partial Thickness Porcine Burns. Acad Emerg Med 2007. [DOI: 10.1197/j.aem.2007.03.748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
14
|
Kline J, Pollyea DA, Stock W, Artz A, Rich E, Godley L, Zimmerman T, Thompson K, Pursell K, Larson RA, van Besien K. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 2006; 37:307-10. [PMID: 16400339 DOI: 10.1038/sj.bmt.1705249] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Alemtuzumab (Campath-1H)-based conditioning regimens are effective in preventing GVHD, but are associated with very high rates of cytomegalovirus (CMV) infection, a major limitation to their use. We evaluated 85 patients receiving conditioning with fludarabine 30 mg/m2/day (day -7 to day -3), alemtuzumab 20 mg/day (day -7 to day -3), and melphalan 140 mg/m2 on day -2. The initial patients received post transplant CMV prophylaxis with high-dose acyclovir. A very high incidence of CMV viremia was observed as has been commonly reported after alemtuzumab-based conditioning. Sixty-seven subsequent patients received pre-transplant ganciclovir and high-dose valacyclovir after engraftment. The cumulative incidence of CMV infection in the valacyclovir cohort was 29%. This compared favorably to the cumulative incidence of 53% in patients receiving only acyclovir (P = 0.004) and to literature data. CMV prophylaxis with pre-transplant ganciclovir and high-dose valacyclovir after engraftment appears effective in preventing the excessive incidence of CMV infection after alemtuzumab-based conditioning regimens.
Collapse
Affiliation(s)
- J Kline
- Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L, Jones D, Del Cerro P, Bennett D, Casey B, Odenike O, Thirman M, Daugherty C, Wickrema A, Zimmerman T, Larson RA, Stock W. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23:5728-38. [PMID: 16009946 DOI: 10.1200/jco.2005.15.602] [Citation(s) in RCA: 120] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE This prospective phase II study evaluated toxicity, relapse rate, progression-free survival, and overall survival after allogeneic transplantation and conditioning with fludarabine, melphalan, and alemtuzumab in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). PATIENTS AND METHODS Fifty-two consecutive adults with AML and MDS were enrolled onto the study. Median age was 52 years (range, 17 to 71 years) and the majority of patients had high-risk disease, comorbidities, and/or modest reduction in performance status. Fifty-six percent of patients had unrelated or mismatched related donors. RESULTS After a median follow-up of 18 months (range, 2 to 34 months), 1-year survival was 48% (95% CI, 34% to 61%), progression-free survival was 38% (95% CI, 25% to 52%), relapse rate was 27% (95% CI, 15% to 40%), and treatment-related mortality was 33% (95% CI, 20% to 46%). The cumulative probability of extensive chronic graft-versus-host disease (GVHD) was only 18% (95% CI, 8% to 40%); extensive chronic GVHD was only observed in recipients of unrelated donor transplants. Performance score and disease status were the major predictors of outcome. High-risk disease (ie, active AML or MDS with > 5% blasts) or even modest decreases in performance status were associated with poor outcomes. Patients with standard-risk leukemia (first or second complete remission) or MDS (< 5% blasts) had excellent outcomes despite unfavorable disease characteristics. CONCLUSION Fludarabine and melphalan combined with in vivo alemtuzumab is a promising transplantation regimen for patients with AML or MDS and low tumor burden. For patients with active disease, this regimen provides at best modest palliation. Despite a low incidence of GVHD, transplantation is still associated with considerable nonrelapse mortality in patients with decreased performance status.
Collapse
Affiliation(s)
- Koen van Besien
- Section of Hematology/Oncology, Department of Health Studies, University of Chicago, IL, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS, Stadler WM, Vogelzang NJ. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant 2005; 35:253-60. [PMID: 15543195 DOI: 10.1038/sj.bmt.1704760] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Nonmyeloablative allogeneic stem cell transplantation (NST) has considerable activity in patients with metastatic renal cell carcinoma (RCC), although there are limited long-term follow-up data. Between February 1999 and May 2003, 18 patients with metastatic RCC underwent 19 matched-sibling NSTs after conditioning with fludarabine and cyclophosphamide with tacrolimus and mycophenolate mofetil as post-transplant immunosuppression. Among the four objective responses, all were partial and have relapsed with a median response duration of 609 days (range, 107-926). All responders are alive at a median of 41 months. Median overall survival for the entire cohort was 14 months. There were four early treatment-related deaths and one late treatment-related death. Eight patients died from progressive disease and five (28%) from treatment-related mortality. Stratifying transplant outcome as early death, intermediate (no response, no early death), or response, the combination of pre-treatment anemia and decreased performance status, was associated with adverse outcome (P = 0.015) and reduced survival (HR 5.4, 95% confidence interval of 1.4 to 21, P = 0.007). Responders demonstrated prolonged survival compared to nonresponders (P = 0.002). NST leads to durable responses in a minority of metastatic RCC patients. Appropriate patient selection is paramount. Anemia and decreased performance status may enable risk stratification.
Collapse
Affiliation(s)
- A S Artz
- University of Chicago Hospitals, Chicago, IL 60637-1470, USA.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
The Graphplan algorithm for generating optimal make-span plans containing parallel sets of actions remains one of the most effective ways to generate such plans. However, despite enhancements on a range of fronts, the approach is currently dominated in terms of speed, by state space planners that employ distance-based heuristics to quickly generate serial plans. We report on a family of strategies that employ available memory to construct a search trace so as to learn from various aspects of Graphplan?s iterative search episodes in order to expedite search in subsequent episodes. The planning approaches can be partitioned into two classes according to the type and extent of search experience captured in the trace. The planners using the more aggressive tracing method are able to avoid much of Graphplan?s redundant search effort, while planners in the second class trade off this aspect in favor of a much higher degree of freedom than Graphplan in traversing the space of 'states' generated during regression search on the planning graph. The tactic favored by the second approach, exploiting the search trace to transform the depth-first, IDA* nature of Graphplan?s search into an iterative state space view, is shown to be the more powerful. We demonstrate that distance-based, state space heuristics can be adapted to informed traversal of the search trace used by the second class of planners and develop an augmentation targeted specifically at planning graph search. Guided by such a heuristic, the step-optimal version of the planner in this class clearly dominates even a highly enhanced version of Graphplan. By adopting beam search on the search trace we then show that virtually optimal parallel plans can be generated at speeds quite competitive with a modern heuristic state space planner.
Collapse
|
18
|
Kline J, Pollyea D, Artz A, Stock W, Rich E, Godley L, Zimmerman T, van Besien K. Ganciclovir and high-dose valacyclovir reduce cytomegalovirus reactivation in patients receiving allogeneic stem cell transplantation with Campath-1H–based conditioning regimens. Biol Blood Marrow Transplant 2005. [DOI: 10.1016/j.bbmt.2004.12.277] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
19
|
Artz A, van Besien K, Zimmerman T, Gajewski T, Rini B, Hu S, Stadler W, Vogelzang N. Long-term follow up after non-myeloablative allogeneic stem cell transplantation for renal cell carcinoma: the university of Chicago experience. Biol Blood Marrow Transplant 2004. [DOI: 10.1016/j.bbmt.2003.12.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
20
|
Harlin H, Artz AS, Mahowald M, Rini BI, Zimmerman T, Vogelzang NJ, Gajewski TF. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cells. Bone Marrow Transplant 2004; 33:491-7. [PMID: 14716341 DOI: 10.1038/sj.bmt.1704385] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Nonmyeloablative allogeneic stem cell transplantation (NST) is thought to be an immunologic therapy in which donor T cells mediate a graft-versus-tumor effect. We recently reported the clinical outcome of a phase II trial of NST in metastatic renal cell carcinoma (RCC). However, the immune response correlates of clinical activity remain unknown. We now describe the analysis of T-cell subsets and T-cell cytokine-producing potential for those patients evaluable for immune monitoring. The incidence of graft-versus-host disease (GVHD) correlated with clinical outcome, with all responders exhibiting chronic GVHD. Following initial tapering of immunosuppression, an increase in the total numbers of CD8+ T cells but not CD4+ T cells was observed among responders compared to nonresponders. In addition, a greater ratio of CD8+ to CD4+ T cells producing IFN-gamma and IL-2 was seen in clinical responders at the time when clinical responses were first detected (day 180 after transplantation). Our results support the hypothesis that the antitumor effects of NST may be mediated by IFN-gamma-producing CD8+ T cells, and indicate that isolation of putative tumor antigen-specific T cells, ideally, should be pursued around day +180.
Collapse
Affiliation(s)
- H Harlin
- Department of Pathology, The University of Chicago, IL 60637, USA
| | | | | | | | | | | | | |
Collapse
|
21
|
Banbula A, Zimmerman T, Novokhatny V. In vitroassessment of inhibitory potential of plasma and whole blood toward exogenous plasmin. J Thromb Haemost 2003. [DOI: 10.1111/j.1538-7836.2003.tb05342.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Petzold U, Blochin B, Zimmerman T, Sabbah A, Karafilidis J, Lavallee N, Hanrahan JP. Efficacy and safety of azelastine in allergic conjunctivitis in children. J Allergy Clin Immunol 2002. [DOI: 10.1016/s0091-6749(02)81613-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
23
|
|
24
|
Dickson DW, Liu W, Hardy J, Farrer M, Mehta N, Uitti R, Mark M, Zimmerman T, Golbe L, Sage J, Sima A, D'Amato C, Albin R, Gilman S, Yen SH. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 1999; 155:1241-51. [PMID: 10514406 PMCID: PMC1867032 DOI: 10.1016/s0002-9440(10)65226-1] [Citation(s) in RCA: 226] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Glial cytoplasmic inclusions (GCI) are the hallmark of multiple system atrophy (MSA), a rare movement disorder frequently associated with autonomic dysfunction. In this study of 21 cases of MSA, GCI were consistently immunoreactive for alpha-synuclein and double-immunostained for ubiquitin and oligodendroglial markers, but not glial fibrillary acidic protein. No statistically significant difference was found in the density of GCI in various brain regions in the two forms of MSA, striatonigral degeneration (SND) and olivopontocerebellar atrophy (OPCA). Postmortem brain samples from 9 cases of MSA were fractionated according to solubility in buffer, Triton-X 100, sodium dodecyl sulfate (SDS), and formic acid, and alpha-synuclein immunoreactivity was measured in Western blots. Total alpha-synuclein immunoreactivity was increased in MSA compared to controls, with no statistically significant difference between SND and OPCA. Most of the increase was due to alpha-synuclein in SDS fractions. In controls this fraction had little or no immunoreactivity. In 7 cases and 4 controls correlations were investigated between quantitative neuropathology and biochemical properties of alpha-synuclein. Surprisingly, the amount of SDS-soluble alpha-synuclein correlated poorly with the number of GCI in adjacent sections. Furthermore, areas with few or no GCI unexpectedly had abundant SDS-soluble alpha-synuclein. These findings provide evidence that modifications of alpha-synuclein in MSA may be more widespread than obvious histopathology. Moreover, these alterations may constitute a biochemical signature for the synucleinopathies.
Collapse
Affiliation(s)
- D W Dickson
- Department of Pathology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Dent LA, Daly CM, Mayrhofer G, Zimmerman T, Hallett A, Bignold LP, Creaney J, Parsons JC. Interleukin-5 transgenic mice show enhanced resistance to primary infections with Nippostrongylus brasiliensis but not primary infections with Toxocara canis. Infect Immun 1999; 67:989-93. [PMID: 9916122 PMCID: PMC96418 DOI: 10.1128/iai.67.2.989-993.1999] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
In this study, interleukin-5 (IL-5) transgenic mice with lifelong eosinophilia were assessed for resistance to primary infections with two tissue-invading nematodes, Nippostrongylus brasiliensis and Toxocara canis. Relative to nontransgenic littermates, three lines of IL-5 transgenic mice with varying degrees of eosinophilia all displayed enhanced resistance to N. brasiliensis. Although the timing of final worm expulsion was similar in transgenic and nontransgenic hosts, intestinal worms in transgenic mice were fewer in number throughout infection, failed to increase in size over the course of the infection, and were much less fecund. In contrast, T. canis larvae were recovered in similar numbers from tissues of transgenic mice with "low" or "high" eosinophilia and from nontransgenic mice. These results and other data suggest that eosinophils can contribute to host resistance to some parasite species. Parasite transit time through the host may correlate with relative sensitivity to eosinophils.
Collapse
Affiliation(s)
- L A Dent
- Departments of Microbiology and Immunology, University of Adelaide, Adelaide, South Australia.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Camras CB, Wax MB, Ritch R, Weinreb R, Robin AL, Higginbotham EJ, Lustgarten J, Stewart WC, Sherwood M, Krupin T, Wilensky J, Cioffi GA, Katz LJ, Schumer RA, Kaufman PL, Minckler D, Zimmerman T, Stjernschantz J. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group. Am J Ophthalmol 1998; 126:390-9. [PMID: 9744372 DOI: 10.1016/s0002-9394(98)00094-4] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
PURPOSE To determine the efficacy and safety of latanoprost treatment for 1 year in glaucoma patients, and to evaluate the effects of switching from timolol to latanoprost therapy. METHODS Latanoprost 0.005% was topically applied once daily without masking for 6 months in 223 patients with elevated intraocular pressure after previous treatment with latanoprost once daily or 0.5% timolol twice daily for 6 months in a multicenter, randomized, double-masked, parallel group study. RESULTS Compared with baseline values before treatment, a significant (P < .0001) diurnal reduction in intraocular pressure of 6 to 8 mm Hg was maintained with minimal fluctuation for the duration of treatment. When treatment was switched from timolol to latanoprost, intraocular pressure was reduced by 1.5 +/- 0.3 mm Hg (mean +/- SEM; 8% change in intraocular pressure; 31% of the intraocular pressure reduction produced by timolol; P < .001) compared with the change in intraocular pressure in patients remaining on latanoprost therapy. Of the patients initially enrolled, 95% successfully completed treatment. There was a slight overall increase in conjunctival hyperemia in patients who switched from timolol to latanoprost, but no change in those who continued latanoprost. The timolol-induced reduction of resting heart rate returned to baseline levels after switching to latanoprost. Of the 247 patients treated with latanoprost during the masked and/or open-label studies, 12 (5%) demonstrated a definite (n = 4) or possible (n = 8) increase in iris pigmentation. CONCLUSIONS Latanoprost is a well-tolerated ocular hypotensive agent that appears to be more effective than timolol in reducing intraocular pressure. The increase in iris pigmentation appears to be harmless but requires further investigation.
Collapse
Affiliation(s)
- C B Camras
- Department of Ophthalmology, University of Nebraska Medical Center, Omaha 68198-5540, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
Orthostatic tremor (OT) is a clinically defined syndrome of leg tremor while standing. Controversy surrounds whether OT is a distinct syndrome or is an essential tremor (ET) variant. We report two patients with OT. Electrophysiological testing included polymyography, accelerometry, nerve conduction, and evoked potential studies. The effects of various maneuvers and body positions on the tremor were assessed. The findings included rapid (15-17 Hz) lower-extremity tremor burst frequency evoked by standing but not by walking or swaying; rapid upper-extremity burst pattern synchronous with lower-extremity bursts; and failure of electrical stimulation or mental concentration to "reset" the tremor. Additionally, there was the novel finding of accelerometric recordings in the legs revealing the same rapid frequency (16-17 Hz) as the electromyographic tremor bursts. Some prior reports have suggested that OT is related to ET by emphasizing a considerable disparity and variability between the accelerometric tremor frequency and the electromyographic burst frequency. In our patients, however, the rapid (15-17 Hz) accelerometer-recorded tremor synchronous with the electromyographic bursts, and also the clinical improvement with clonazepam but not beta blockers or mysoline, and the lack of a family history of ET provide support that OT is distinct from ET.
Collapse
Affiliation(s)
- H W Sander
- Department of Neurology, Saint Vincent's Hospital of New York, New York Medical College, NY 10011, USA
| | | | | | | | | | | |
Collapse
|
28
|
Syed N, Murphy J, Zimmerman T, Mark MH, Sage JI. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998; 13:336-8. [PMID: 9539350 DOI: 10.1002/mds.870130222] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
We report our long-term experience using enteral levodopa infusions in 22 patients with Parkinson's disease and severe motor fluctuations. Amelioration of intractable dyskinesias was the most important factor that determined whether patients chose to continue using the infusion pump system. Mechanical and physical problems associated with enteral access were the most common reasons for which patients discontinued pump use. Nearly all patients continued to have dramatically increased on time for the duration of follow up, suggesting that technically less-cumbersome systems that provide continuous dopaminergic stimulation are worthwhile and should be developed.
Collapse
Affiliation(s)
- N Syed
- Department of Neurology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick 08901, USA
| | | | | | | | | |
Collapse
|
29
|
Zimmerman T, Putland LC, Hughes JR. Russian and local nurse educators exchange ideas. Nurs Spectr (Wash D C) 1997; 7:9. [PMID: 9431182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
30
|
Williams SF, Lee WJ, Bender JG, Zimmerman T, Swinney P, Blake M, Carreon J, Schilling M, Smith S, Williams DE, Oldham F, Van Epps D. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. Blood 1996; 87:1687-91. [PMID: 8634412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Cytopenia after high-dose chemotherapy and autologous stem cell reinfusion is a major cause of morbidity. Ex vivo cultured expansion and differentiation of CD34+ peripheral blood progenitor cells (PBPC) to neutrophil precursors may shorten the neutropenic period further. We explored the use of these ex vivo cultured PBPCs in nine patients with metastatic breast cancer. All underwent PBPC mobilization with cyclophosphamide, VP-16, and G-CSF. Subsequently, they underwent four to five apheresis procedures. One apheresis product from each patient was prepared using the Isolex 300 Magnetic Cell Separation System (Baxter Immunotherapy, Irvine, CA) to obtain CD34+ cells. These cells were then cultured in gas permeable bags containing serum-free X-VIVO 10 (BioWhittaker, Walkersville, MD) medium supplemented with 1% human serum albumin and 100 ng/mL PIXY321. At day 12 of culture the mean fold expansion was 26x with a range of 6 to 64x. One patient's cells did not expand because of a technical difficulty. The final cell product contained an average of 29.3% CD15+ neutrophil precursors with a range of 18.5% to 48.1%. The patients underwent high-dose chemotherapy with cyclophosphamide, carboplatin, and thiotepa. On day 0, the cryopreserved PBPCs were reinfused and on day +1 the 12-day cultured cells were washed, resuspended, and reinfused into eight of nine patients. One patient was not infused with cultured cells. The mean number of cultured cells reinfused was 44.6 x 10(6) cells/kg with a range of 0.8 to 156.6 x 10(6) cells/kg. No toxicity was observed after reinfusion. The eight patients have recovered absolute neutrophil counts > 500/microL on a median of 8 days (range 8 to 10 days); the median platelet transfusion independence occurred on day 10 (range 8 to 12 days) and platelet counts > 50,000/microL were achieved by day 12 (range 9 to 14) for the seven patients whose platelet counts could be determined. Expanded CD34+ selected PBPC can be obtained and safely reinfused into patients.
Collapse
Affiliation(s)
- S F Williams
- Department of Medicine, University of Chicago Medical Center, IL, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
May P, London EB, Zimmerman T, Thompson R, Mento T, Spreat S. A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. Ann Clin Psychiatry 1995; 7:155-60. [PMID: 8721888 DOI: 10.3109/10401239509149620] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
In a naturalistic study of 23 severely and profoundly mentally retarded adult male patients undergoing slow "diagnostic" neuroleptic taper, it was determined that at least 60% could eventually be managed without psychoactive medication. However, many of these demonstrated a remarkably long, but nonetheless transient, period of worsening. This suggests that behavioral deterioration during drug reduction trials does not always indicate a need for chronic neuroleptic maintenance since these behaviors may return to baseline without pharmacological intervention. On the other hand, 40% demonstrated persistent (> 2 years) behavioral worsening. Those individuals who demonstrated persistent deterioration had been generally well controlled on neuroleptics, were somewhat older, and were receiving a higher baseline dose. Most of these persistently worsened subjects currently require some type of psychoactive medication (although only two have been returned to neuroleptics).
Collapse
Affiliation(s)
- P May
- Department of Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, USA
| | | | | | | | | | | |
Collapse
|
32
|
Abstract
Intellectual abilities of 300 children with serious emotional disorders, referred to either psychiatric day- or inpatient-hospital treatment, were compared. Comparisons also were made to WISC-R standardization data. The findings indicated that children referred to inpatient settings were similar in intellectual competency to children in day treatment. Also, children with serious emotional disorders did not appear to differ strongly in clinically meaningful ways from the WISC-R standardization sample, a finding that replicates results of other investigators. Three distinct, clinically useful profiles emerged from a cluster analysis of the total group that may be practical in planning educational and therapeutic interventions in treatment settings for seriously disturbed children. The profiles underscored the wide range of intellectual abilities represented among these children.
Collapse
Affiliation(s)
- G D Zimet
- Indiana University School of Medicine, Indianapolis 46202-5225
| | | | | | | | | |
Collapse
|
33
|
Abstract
OBJECTIVE To identify morning glory syndrome, an uncommon optic disc anomaly. Generally, it is an isolated ocular abnormality; however, some cranial facial and neurologic associations have been reported. PATIENTS We herein report two patients with morning glory syndrome and associated pituitary dwarfism. In one patient, the pituitary insufficiency was secondary to compression of the pituitary gland by a basal encephalocele; in the second patient, causative factors were not identified. CONCLUSIONS Patients with morning glory syndrome should have a complete general physical examination and growth evaluation so that early recognition and treatment of the patient with pituitary dwarfism can occur.
Collapse
Affiliation(s)
- H S Eustis
- Department of Ophthalmology, Ochsner Clinic, New Orleans, La
| | | | | |
Collapse
|
34
|
Abstract
Sustained hematopoiesis can be restored after dose-intensive chemotherapy utilizing stem cells from either bone marrow and/or peripheral blood. Numerous reports have demonstrated the effectiveness of peripheral blood progenitors (PBPC) in restoring hematopoiesis. Here, we review data comparing the recovery among patients rescued with various stem cell sources after dose-intensive therapy. PBPC used alone or to augment autologous bone marrow to achieve timely hematopoietic recovery after dose-intensive therapy can result in shortened hospital stays, decreased transfusion requirements, and antibiotic usage. This will lead to increased application of dose-intensive therapy either singly or in multiple courses to treat various malignancies.
Collapse
Affiliation(s)
- S F Williams
- Department of Medicine, University of Chicago Medical Center, IL 60637
| | | | | | | |
Collapse
|
35
|
Abstract
We are reporting a neurophysiologic analysis of two patients presenting with thoracoabdominal spontaneous muscle jerks. Polymyographic recordings showed myoclonic bursts with onset in the upper rectus abdominis or lower intercostal muscles followed by rostral propagation to the upper intercostal and caudal propagation to the abdominal muscles by slowly conducting pathways. Jerk-locked back-averaging did not show time-locked cortical or premovement potentials. Peroneal somatosensory evoked response, C-reflex, and intercostal nerve conduction were normal. These findings suggest a generator for the myoclonus in the midthoracic region of the spinal cord with up and down propagation by slowly conducting pathways, such as propriospinal fibers. This type of spinal myoclonus may thus be termed "propriospinal myoclonus," as suggested by Brown et al.
Collapse
Affiliation(s)
- S Chokroverty
- Department of Neurology and Clinical Neurophysiology, Robert Wood Johnson Medical School, New Brunswick, NJ
| | | | | | | |
Collapse
|
36
|
Lewis P, Teinert DG, Fadol A, Seidel J, Quint L, Zimmerman T, Hamilton M. Successful educational/developmental strategies used in a critical care residency program. Crit Care Nurse 1992. [DOI: 10.4037/ccn1992.12.5.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
37
|
Lewis P, Teinert DG, Fadol A, Seidel J, Quint L, Zimmerman T, Hamilton M. Successful educational/developmental strategies used in a critical care residency program. Crit Care Nurse 1992; 12:106-8, 111, 115 passim. [PMID: 1597056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
38
|
Abstract
Secondary bone grafting of residual alveolar clefts has become an integral part of the comprehensive care of children born with facial clefting. Although indications and timing may remain somewhat controversial, bone grafting during the period of mixed dentition has gained widespread acceptance. A number of bone graft sites have been proposed; each has its enthusiastic proponents. We believe that cancellous bone harvested from the ilium provides optimal material to achieve successful alveolar bone grafting. Unfortunately, this site has been associated with significant morbidity, primarily pain, which can prolong a patient's hospitalization. We relate our experience from two centers encompassing 24 patients who underwent percutaneous harvesting of corticocancellous bone grafts from the ilium. With this method we were successful in obtaining adequate quantities of corticocancellous bone with the Craig bone biopsy needle regardless of the cleft size. Each patient was able to ambulate without difficulty within hours of surgery. We are currently performing alveolar bone grafting as an outpatient procedure employing this technique. In addition, we believe this method has particular usefulness in Third World countries.
Collapse
Affiliation(s)
- S R Thaller
- Department of Surgery, University of California Davis Medical Center, Sacramento
| | | | | | | |
Collapse
|
39
|
Silverstone D, Zimmerman T, Choplin N, Mundorf T, Rose A, Stoecker J, Kelley E, Lue J. Evaluation of once-daily levobunolol 0.25% and timolol 0.25% therapy for increased intraocular pressure. Am J Ophthalmol 1991; 112:56-60. [PMID: 1882923 DOI: 10.1016/s0002-9394(14)76213-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
In a three-month, double-masked, randomized clinical trial, we evaluated the once-daily ocular hypotensive efficacy of 0.25% levobunolol and 0.25% timolol in 80 patients with open-angle glaucoma or ocular hypertension. Thirty-seven of the 39 patients (95%) in the 0.25% levobunolol group and 35 of the 41 patients (85%) in the 0.25% timolol group successfully completed the three-month study period. The overall mean decrease in intraocular pressure was 5.3 mm Hg (22%) in the 0.25% levobunolol group and 5.4 mm Hg (22%) in the 0.25% timolol group. This difference was not statistically significant. In both treatment groups, effects on mean heart rate and blood pressure were minimal. The data suggest that levobunolol 0.25% and timolol 0.25%, administered once daily, are equally effective in the treatment of open-angle glaucoma and ocular hypertension.
Collapse
Affiliation(s)
- D Silverstone
- Department of Ophthalmology and Visual Sciences, Yale University School of Medicine, New Haven, Connecticut
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
We retrospectively compared the clinical state of 14 patients with Parkinson's disease who took pergolide continuously for 63 +/- 17 months (Group I) to that of 12 similar patients who started pergolide and then stopped it after 60 +/- 5 days (Group II). Disability measured during the "on" state did not worsen during the observations period in Group I patients, whereas disability in Group II showed significant deterioration. There were no significant differences in the progression of motor fluctuations between the two groups. Combination treatment with pergolide and levodopa is effective long-term symptomatic therapy for advanced Parkinson's disease and deserves more rigorous study to determine whether or not it also retards progression of Parkinson's disease.
Collapse
Affiliation(s)
- T Zimmerman
- Department of Neurology, UMDNJ--Robert Wood Johnson Medical School, New Brunswick 08903
| | | |
Collapse
|
41
|
Lapidus AL, Novak Z, Savel'ev MM, Lyukke B, Zimmerman T, Pirozhkov SD, Manek K�, Sominskii SD, Rar LF. Synthesis of hydrocarbons and alcohols from CO and H2 in the presence of CO-Rh catalysts. Russ Chem Bull 1990. [DOI: 10.1007/bf00961473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
42
|
Abstract
To determine the role insulin resistance may play in the catabolic effect of high-dose prednisone therapy, healthy volunteers were studied on four occasions with the hormone-clamp technique at two insulin infusion rates. Subjects were studied after 5 days of prednisone (60 mg/day) or no steroid treatment and were infused with somatostatin, glucagon, growth hormone, [3H]glucose, [14C]leucine, and insulin (0.1 or 0.2 mU.kg-1.min-1). At each rate of insulin infusion, the rate of leucine oxidation was increased (P less than .001) after steroid treatment. Leucine flux, an indicator of whole-body proteolysis, was similar in the presence or absence of steroid treatment (2.26 +/- 0.08 vs. 2.13 +/- 0.04 mumol.kg-1.min-1, respectively) at the lower rate of insulin infusion but was higher during steroid treatment (2.18 +/- 0.06 vs. 1.84 +/- 0.13 mumol.kg-1.min-1) at the 0.2-mU.kg-1.min-1 insulin infusion. Steroid pretreatment had no significant effect on the nonoxidative rates of leucine disappearance. These data provide strong evidence that the protein wasting associated with glucocorticosteroid therapy is in part the result of steroid-induced resistance to the antiproteolytic effect of insulin and an increase in the oxidation (and thus wasting) of one essential amino acid, leucine.
Collapse
Affiliation(s)
- T Zimmerman
- Department of Pediatrics, Mayo Clinic and Foundation, Rochester, Minnesota 55905
| | | | | | | | | |
Collapse
|
43
|
Long D, Zimmerman T, Spaeth G, Novack G, Burke PJ, Duzman E. Minimum concentration of levobunolol required to control intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 1985; 99:18-22. [PMID: 3881033 DOI: 10.1016/s0002-9394(14)75860-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
In a double-masked, randomized, comparison titration study to determine the effective dose of topically applied levobunolol, three concentrations of levobunolol (0.25%, 0.5%, and 1%) and of timolol (0.125%, 0.25%, and 0.5%) were evaluated in patients with mild open-angle glaucoma or ocular hypertension. Following a washout of ocular hypotensive medication, twice-daily treatment in both eyes was initiated with the lowest of the three doses of either drug. The concentration was increased if intraocular pressure remained uncontrolled. Intraocular pressure was controlled in 63% (15 of 24) of the patients tested with the lowest concentration of levobunolol and 69% (18 of 26) with the lowest concentration of timolol. Overall, 75% (18 of 24) of the patients in the levobunolol group and 73% (19 of 26) of the patients in the timolol group had adequately controlled intraocular pressure. At the lowest concentrations tested, mean decreases from baseline in intraocular pressure ranged from 6 to 8 mm Hg in both treatment groups.
Collapse
|
44
|
Budde U, Schaefer G, Mueller N, Egli H, Dent J, Ruggeri Z, Zimmerman T. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64:981-5. [PMID: 6333259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
An acquired hemorrhagic disorder developed in two patients in association with postsplenectomy thrombocytosis and leukocytosis during the course of the myeloproliferative syndrome. The presence of acquired von Willebrand's disease in these individuals was demonstrated by a decrease or absence of the larger von Willebrand factor (vWF) multimers, alteration of the repeating vWF multimeric "triplet," decreased ristocetin cofactor activity (vWF:RCo), and prolonged bleeding time. The bleeding stopped in both patients after treatment with either 1-deamino-[8-D-arginine]-vasopressin (DDAVP) or Cohn fraction I. Treatment with thrombocytapheresis and azathioprine or busulfan resulted in reduction of the elevated platelet and white cell counts and was associated with partial correction of the vWF abnormalities and remission of the hemostatic abnormalities. In five additional patients with the myeloproliferative syndrome, but without bleeding symptoms, large multimers of plasma vWF were diminished also. These findings suggest that acquired von Willebrand's disease should be considered when a bleeding diathesis develops during the course of the myeloproliferative syndrome.
Collapse
|
45
|
Kandarakis A, Zimmerman T. Non-pupillary block angle-closure glaucomas and their treatment by laser. Part II: Laser gonioplasty technique. Ann Ophthalmol 1984; 16:914. [PMID: 6508084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
46
|
Cammer W, Kahn S, Zimmerman T. Biochemical abnormalities in spinal cord myelin and CNS homogenates in heterozygotes affected by the shiverer mutation. J Neurochem 1984; 42:1372-8. [PMID: 6200571 DOI: 10.1111/j.1471-4159.1984.tb02797.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Myelin was purified from the spinal cords of normal mice and mice heterozygous for the shiverer mutation, and measurements were made of the major myelin proteins and lipids and the specific activities of three myelin-associated enzymes. The myelin purified from the spinal cords of the heterozygotes (shi/+) was deficient by 30-40% in yield and had an apparently unique composition. In particular, when compared with normal mouse spinal cord myelin, there were more high-molecular-weight protein, less myelin basic protein, a higher protein-to-lipid ratio, and higher specific activities of 2',3'-cyclic nucleotide-3'-phosphohydrolase (EC 3.1.4.37) and carbonic anhydrase (EC 4.2.1.1) in the myelin purified from the shi/+ animals. These abnormalities were reflected in the composition of shi/+ whole spinal cord, where the protein-to-lipid ratio was intermediate between the respective values for +/+ and shi/shi spinal cords. Whole brains from shi/+ mice showed deficiencies in galactocerebroside and galactocerebroside sulfate and an increase in total phospholipid, and the lipid composition in the brains of the shi/shi mice was similar to that reported for another dysmyelinating mutant, quaking. The findings provide the first values for the lipids in normal mouse spinal cord myelin and show that heterozygotes are affected by the shiverer mutation. The observations imply that there can be considerable deviation from the normal CNS myelin content and composition without apparent qualitative morphological abnormalities or loss of function and that the amount of myelin basic protein available during myelination may influence the incorporation of other constituents into the myelin membranes.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
47
|
Mandelkorn RM, Hoffman ME, Olander KW, Zimmerman T, Harsha D. Inheritance and the pigmentary dispersion syndrome. Ann Ophthalmol 1983; 15:577-82. [PMID: 6571433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
We studied 23 patients in four families and have found that ten of these patients fulfill criteria for the pigmentary dispersion syndrome. Affected patients had characteristics associated with the pigmentary dispersion syndrome, which are: peripheral slit-like iris transillumination defects, increased trabecular meshwork pigmentation, Krukenberg spindle, myopia, and elevated intraocular pressure. We observed this syndrome to be transmitted in a direct linear manner from parent to sibling in three of the four families. The transmission of this syndrome was found to be independent of refractive error, iris color, and sexual predilection; all of which will be presented.
Collapse
|
48
|
Abstract
Elevated intraocular pressure after keratoplasty is a well-recognized phenomenon both in aphakia and in combined lens extraction and penetrating keratoplasty. Ninety-two consecutive cases of penetrating keratoplasty procedures were studied. These were randomly assigned to group A or B. Group A received a donor transplant 0.5 mm larger than the recipient bed. Group B received donor buttons equal in size to the recipient bed. Intraocular pressure was measured preoperatively and daily until the patients were discharged. Group A, which had aphakic penetrating keratoplasty or the combined procedure (0.5-mm larger button), also had significantly lower intraocular pressures (P less than .001) than group B (same size button). There was no difference in postoperative intraocular pressure between groups A and B for those who had phakic penetrating keratoplasties. A larger donor size can alleviate induced "aphakic keratoplasty glaucoma."
Collapse
|
49
|
Gans BM, Zimmerman T, Stolov WC. Urinary catheterization in severe sphincter spasticity: report of two cases. Arch Phys Med Rehabil 1975; 56:498. [PMID: 1200821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
50
|
Greer S, Schildkraut I, Zimmerman T, Kaufman H. 5-Halogenated analogs of deoxycytidine as selective inhibitors of the replication of herpes simplex viruses in cell culture and related studies of intracranial herpes simplex virus infections in mice. Ann N Y Acad Sci 1975; 255:359-65. [PMID: 171995 DOI: 10.1111/j.1749-6632.1975.tb29243.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|